New Treatment for Mantle Cell Lymphoma Using Alisertib, Ibrutinib, and Rituximab
Author Information
Author(s): Subramani Baskaran, Conway Patrick J., Al-Khinji Aisha, Zhang Kun, Pandey Ritu, Mahadevan Daruka
Primary Institution: Mays Cancer Center, University of Texas Health San Antonio
Hypothesis
Combining alisertib with ibrutinib and rituximab will enhance treatment efficacy in mantle cell lymphoma (MCL) patients resistant to ibrutinib.
Conclusion
The combination of alisertib, ibrutinib, and rituximab significantly improves tumor growth inhibition and survival in mantle cell lymphoma models compared to ibrutinib alone.
Supporting Evidence
- Alisertib plus ibrutinib showed synergistic effects in inhibiting MCL cell lines.
- The combination of alisertib and ibrutinib significantly reduced tumor growth in mouse models.
- Patients with ibrutinib resistance may benefit from the addition of alisertib and rituximab.
Takeaway
Researchers found that using three medicines together can help people with a type of cancer called mantle cell lymphoma, especially when one of the medicines stops working.
Methodology
The study involved in vitro assays on MCL cell lines and in vivo testing using a mouse xenograft model to evaluate the effects of drug combinations on tumor growth and survival.
Limitations
The study primarily focused on specific cell lines and a mouse model, which may not fully represent human responses.
Statistical Information
P-Value
p < 0.0001
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website